Clinical Trials Logo
  1. Home
  2. Asthma Bronchiale
  3. NCT00476073

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Asthma Bronchiale Clinical Trial

Clinical Trial Summary

Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.

Clinical Trial Description

This is a study involving a 12 week treatment phase. During the treatment phase subjects receive FLUTIFORM® or Sertetide®. Efficacy will be assessed by lung function tests and asthma symptoms, sleep disturbance. Safety will be assessed by adverse events, vital signs, lab tests and ECGs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00476073
Study type Interventional
Source Mundipharma Research Limited
Contact
Status Completed
Phase Phase 3
Start date April 2007
Completion date January 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00563056 - An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma Phase 3